Why the study?
Pulmonary vein isolations are being performed using a high-power, short duration strategy, but its clinical efficacy and safety compared with a low-power long duration approach in patients with paroxysmal atrial fibrillation needed evaluation.
Does high-power short-duration ablation reduce the recurrence of atrial arrhythmias compared to low-power long-duration ablation in patients with paroxysmal atrial fibrillation?
Does high-power short-duration ablation reduce the recurrence of atrial arrhythmias compared to low-power long-duration ablation in patients with paroxysmal atrial fibrillation?
High-power short-duration ablation for pulmonary vein isolation significantly reduces procedure time without compromising clinical efficacy or safety compared to a low-power long-duration strategy.
Background Pulmonary vein isolations (PVI) are being performed using a high-power, short duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of a HPSD vs low-power long duration (LPLD) approach to PVI in patients with paroxysmal atrial fibrillation (AF). Methods Patients were grouped according to a HPSD (≥40 W) or LPLD (≤ 35 W) strategy. The primary endpoint was the one-year recurrence of any atrial arrhythmia lasting ≥ 30 seconds, detected using three 14-day ambulatory continuous ECG monitoring. Procedural and safety endpoints were also evaluated. The primary analysis were regression models incorporating propensity scores yielding adjusted relative risk (RR a ) and mean difference (MD a ) estimates. Results Of the 398 patients included in the AWARE Trial, 173 (43%) underwent HPSD and 225 (57%) LPLD ablation. The distribution of power was 50 W in 75%, 45 W in 20% and 40 W in 5% in the HPSD group, and 35W with 25W on the posterior wall in the LPLD group. The primary outcome was not statistically significant at 30.1% vs 22.2% in HPSD and LPLD group with RR a 0.77 (95% confidence interval [CI]) 0.55-1.10; p=0.165). The secondary outcome of repeat catheter ablation was not statistically significant at 6.9% and 9.8% (RR a 1.59 [95% CI 0.77-3.30]; p=0.208) respectively. The incidence of any ECG documented AF during the blanking period was numerically lower in the HPSD group: 1.7% vs 8.0% (RR a 3.95 [95% CI 1.00-15.61; p=0.049). The total procedure time was significantly shorter in the HPSD group (MD a 97.5 minutes [95% CI 84.8-110.4)]; p<0.0001) with no difference in adjudicated serious adverse events. Conclusions A HPSD strategy was associated with significantly shorter procedural times with similar efficacy in terms of clinical arrhythmia recurrence. Importantly, there was no signal for increased harm with a HPSD strategy. Graphical Abstract Non-standard Abbreviations and Acronyms HPSD: High-Power Short Duration; LPLD: Low-Power Long Duration; QOL: Quality of Life; WACA: wide area circumferential ablation; PVI: Pulmonary Vein Isolation; AF: Atrial Fibrillation Clinical Perspective What is known -The optimal power and duration of ablation lesions to produce durable pulmonary vein isolation remain unclear. -Nonrandomized studies have suggested clinical efficacy with high-power short duration radiofrequency ablation vs low-power long duration. What this study adds -In this large substudy of the AWARE Trial, a high-power short duration radiofrequency ablation strategy was found to be similarly effective as a low-power long duration strategy with no difference in time to first recurrence of any AF lasting ≥ 30 seconds. -Procedural were substantially reduced with high-power short duration ablation with no significant difference in overall complication rates.
No takes yet. Share an insight, caveat, or question.
Joza et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: